 |
|
|
|
|
|
|
|
While there are often no symptoms in an early stage of the disease, those of a condition that are more advanced may include:
- Frequent urination, particularly at night;
- An interrupted or weak flow of urine;
- Difficulty urinating;
- Pain or a burning sensation while urinating;
- Blood in the semen or urine;
- Urinary or fecal incontinence;
- Numbness or weakness in the legs and/or feet;
- Painful ejaculation;
- A “nagging pain” in the back, hips, ribs, pelvis, or other bones; and
- Impotence - trouble having or keeping an erection.
If you have experienced any symptoms from the list above, speak with your healthcare provider. Your Doctor will most likely conduct some tests to diagnose your condition.
|
|
|
|
|
Indications and Usage
TRELSTAR® Depot and TRELSTAR®
LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR
Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy
or estrogen administration are either not indicated or unacceptable to the patient. |
|
|
|
Safety Information
|
|
The most commonly reported adverse events associated with the use of TRELSTAR®
Depot/TRELSTAR® LA included hot flushes (58.6%/73.0%), skeletal pain
(12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%),
and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or
may become pregnant as well as patients who are hypersensitive to triptorelin, other
LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock
and angioedema have been received since 1986 (global experience) . As with all LHRH
agonists, triptorelin causes an initial transient increase in testosterone levels.
Patients may experience the onset or exacerbation of symptoms during this period,
including bone pain, neuropathy, hematuria, spinal cord compression, or urethral
or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or
urinary tract obstruction should be closely observed. |
|
|
|
|
|
|
|
|
|
